Company Overview: Mesoblast

Industry News

12 May

Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study

Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its proprietary allogeneic mesenchymal precursor cells (MPCs) can reduce inflammation and reverse abnormal function of blood vessels, including the coronary arteries, in a previously published sheep model...

Read more

30 Jan


Mesoblast’s business model is very similar to classical pharmaceutical drug development: to deliver effective products with low manufacturing costs of goods and high margins. This has been achieved as a result of two technical advantages that are unique to the patented stem cell technology- the ability of the cells...

Read more

29 Apr

Mesoblast (MBLTY) Provides Update on Clinical Programs of Prochymal for Crohn’s Disease and Acute Graft Versus Host Disease

Regenerative medicine company Mesoblast Limited (asx:MSB)(usotc:MBLTY) today provided an update on its clinical programs using the product Prochymal®, which was acquired as part of the entire culture-expanded mesenchymal stem cell (MSC) business of Osiris Therapeutics OSIR +2.98% by the Mesoblast Group. A key aspect of the strategic rationale for...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address